||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Amryt Pharma Share Discussion Threads
Showing 801 to 824 of 825 messages
|Here's the link from post #693 (above):
|PROACTIVITY - Amryt Pharma on the fast-track to commercial success
09th December 2016
Dear Proactive Investor
It can take years for a small, aspiring drug developer with a promising compound (and a plan) to cross the Rubicon to commercial success.
Amryt Pharma has passed that landmark in a quick-fire 18 months.
More than that, it has managed two acquisitions, two stock market listings and raised €43mln.
Oh, and it has put a heavy-hitting team together that supports a very ambitious growth strategy. Editor Ian Lyall has more..
|"Some experts say Amicus’s product has a slightly inferior profile to Episalvan, yet it is valued by analysts at €326mln (US$350mln).
"Amyrt’s market capitalisation currently stands at €48mln, so there’s a valuation disconnect there."
Jeez...link blocked again.Just Google "Amryt Pharma on the fast-track to commercial success" for pro active website.|
|Nice little 20p Friday finish maybe?|
|Yes, feeling much more confident after the last two RNSs. Completely different picture now. Happy to hold.|
|I agree, which is why I stayed in. Why JP has is a mystery.
|Only time will tell, but my gut tells me we could be on a winner (and a big winner) with AMYT. Fingers crossed!|
|Little reversal on selling|
|Only a small pullback today on lower volume. Volume today well down on that of Friday, Monday & yesterday, which was very high.
The shares are circa 40% higher than last Thursday close following the good news issued on Friday & Monday so profit taking is to be expected. How much further the share price drops I have no idea. Me? I'm not selling any of my shares. I'm not worried if it drops back to 14p as I'm holding my shares for the longer term as AMYT has a great BoD and very good prospects.
Shares go up on good news and tend to gradually drift back until the next news is issued. However they can also be re-rated upwards following good news if they are considered undervalued. That could happen here.|
|Down? Not possible, surely?|
|And there is your tick up. Will we make it back to 20p today?|
|Nice buy gone through.|
|What? No tick up today?|
|Do we have the correct sales force to sell this product. Drug reps are expensive and need training.slightly different to selling skin care products.|
|JPNo, that's my investment strategy here!|
RED then U/C & now BLUE!|
|What, no RNS today? Shocking.|
|I'd imagine it's aimed at investors!
It's mostly you JP, that thinks the bod are doing nothing.
Maybe you should buy a retailer.
|I'm predicting a slow rise into the start of the phase 3 for episalvan. Hopefully there will be more 'transformational' news in the interim!|
|rossannan. I take it you last comment was aimed at the bod's?|
|Think the trick here is to go back to sleep.|
|Amryt Pharma (AMYT.L, 18.5p) – Speculative Buy
Amryt Pharma plc, the clinical stage specialty pharmaceutical company focused on best in class treatments for orphan diseases, yesterday announced that it has secured an agreement with Aegerion Pharmaceuticals, Inc. ('Aegerion'), the NASDAQ-listed biopharmaceutical company, for the exclusive rights to sell Aegerion's drug, LOJUXTA (lomitapide), across the European Economic Area, Middle East and North Africa, Turkey and Israel. Under the Licence Agreement, Amryt will make royalty payments to Aegerion, paid quarterly, based on a percentage of sales, and once-off commercial milestone payments, subject to achieving certain sales targets. The Licence Agreement has an initial term until 1 January 2024, and upon expiry, Amryt has option to extend the Agreement for a further 5 years with the right to extend in further 5 year periods, subject to certain conditions. Amryt will also take on the ongoing regulatory and post-marketing obligations and commitments in support of LOJUXTA. LOJUXTA was approved in the EU since 2013 for the treatment for Homozygous Familial Hypercholesterolemia ('HoFH'), a very rare life-threatening genetic disorder that impairs the body's ability to remove LDL cholesterol ("bad" cholesterol) from the blood. This typically results in extremely high blood LDL cholesterol levels leading to aggressive and premature narrowing and blocking of arterial blood vessels manifesting as cardiovascular disease. If left untreated, heart attacks, strokes or sudden death may occur in childhood or early adulthood (mean life expectancy of 18 years, while with current treatment options including statin drugs, PCSK9 inhibitors and apheresis (a blood filtration technique similar to dialysis), life expectancy increase to average 45-48 years but there are not adequate to control LDL cholesterol levels in some patients, particularly those with the most severe genetic mutations. Amryt's CEO, Joe Wiley commented "We are delighted to announce this landmark licensing deal. It transforms Amryt into a fully-fledged commercial orphan pharma company and comes only eight months after Amryt's IPO in April. This agreement is tremendously exciting and underlines our clear focus on building our portfolio of medicines to treat rare and orphan diseases, where there is large unmet medical need. We look forward providing a further update in due course".
Our view: Another significant announcement from Amryt, following last Friday's €20m Facility Agreement reached with the European Investment Bank. Yesterday's Licence Agreement will add to the Group's growing portfolio of orphan products and has effectively transformed Amryt into fully-integrated sustainable, commercial pharmaceutical Group. Management said LOJUXTA is expected to be immediately cash generative and its ongoing regulatory and post-marketing commitments will all be funded from the own cashflow, rather than at Group level given that it requires relatively limited additional commercial, medical and regulatory infrastructure. Royalties on net sales are "not single digit but not substantial" said Rory Nealon (CFO/COO) during analyst meeting, while noting EBITDA margin to be expected should be around 20% of revenue, although "much higher than 40%" at the gross level. HoFH is a very rare, genetic disorder which starts in utero and causes premature cardiovascular disease. Historically, HoFH was estimated to occur in about 1 in 1 million people worldwide, but more recent studies suggest it may affect up to 1 in 300,000 people. The total market for LOJUXTA for HoFH indication is estimated at €50m and in Q3 2016, Aegerion generated US$22m in net product sales of lomitapide, of which, 15% was from prescriptions written outside of the US. Of this, 30% comes from Brazil and 70% was from the territories now being licensed to Amryt. With currently available treatment showing limited efficacy for some patients in controlling their LDL cholesterol levels, there is significant potential for the LOJUXTA to become a mainstay treatment for patients, having showed a 40-50% reduction in LDL cholesterol at 26 weeks after dosage during Phase 3 clinical trial, following which it remained stable at 126 weeks. The Licence Agreement for LOJUXTA will be cash generative from the day one and has significantly de-risked the Group. With Amryt's impressive Board of Directors, we believe the Group is proceeding in its plan to replicating Shire Pharmaceutical's original model. Following the €20m Facility Agreement from EIB announced on Friday, the Group is fully funded, and yesterday's announcement marks the start of a new stream of announcements going forward. The Phase III clinical trial for Episalvan in Epidermolysis Bullosa is expected to commence in Q1 FY2017 and we look forward to further updates in due course. We are excited by the Group's recent progress and reiterate our Speculative Buy rating on the shares.|
|Well, that's the end of that mini rise. Amazing how nothing can drop an aim share 40% in a day but when really good news arrive most aim shares move a few % Up then drop back down. If I didn't know any better I'd say there is a slight bit of manipulation when it comes to aim shares.|